StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Needham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'
August 3, 2018 7:27 AM
Needham & Company upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Hold to Buy with a price target of $54.00.Analsyt Serge Belanger ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Upgrades
Upgrades
Next Articles
Pacira Pharmaceuticals (PCRX) PT Raised to $43 at Mizuho Securities
August 7, 2018 4:11 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $85 at Wedbush
August 6, 2018 7:48 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC Capital
August 3, 2018 7:56 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $53 at Seaport Global Securities
August 3, 2018 7:23 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $40 at BMO Capital
August 3, 2018 6:57 AM
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at Barclays
August 3, 2018 5:09 AM
Form 10-Q Pacira Pharmaceuticals, For: Jun 30
August 2, 2018 3:41 PM
Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
August 2, 2018 8:14 AM
